Literature DB >> 24045708

Biomarkers: new biomarker for Sjögren's syndrome--time to treat patients.

Frans G M Kroese1, Hendrika Bootsma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24045708     DOI： 10.1038/nrrheum.2013.143

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

Review 1.  Topical and systemic medications for the treatment of primary Sjögren's syndrome.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Antoni Sisó-Almirall; Xavier Bosch; Athanasios G Tzioufas
Journal:  Nat Rev Rheumatol       Date:  2012-05-01       Impact factor: 20.543

2.  Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome.

Authors:  R P E Pollard; W H Abdulahad; H Bootsma; P M Meiners; F K L Spijkervet; M G Huitema; J G M Burgerhof; A Vissink; F G M Kroese
Journal:  Ann Rheum Dis       Date:  2013-07-17       Impact factor: 19.103

3.  EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial.

Authors:  R V Moerman; S Arends; P M Meiners; E Brouwer; F K L Spijkervet; F G M Kroese; A Vissink; H Bootsma
Journal:  Ann Rheum Dis       Date:  2013-08-12       Impact factor: 19.103

4.  EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome.

Authors:  Raphaèle Seror; Philippe Ravaud; Simon J Bowman; Gabriel Baron; Athanasios Tzioufas; Elke Theander; Jacques-Eric Gottenberg; Hendrika Bootsma; Xavier Mariette; Claudio Vitali
Journal:  Ann Rheum Dis       Date:  2009-06-28       Impact factor: 19.103

Review 5.  The interferon signature in autoimmune diseases.

Authors:  Lars Rönnblom; Maija-Leena Eloranta
Journal:  Curr Opin Rheumatol       Date:  2013-03       Impact factor: 5.006

6.  EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome.

Authors:  Raphaèle Seror; Philippe Ravaud; Xavier Mariette; Hendrika Bootsma; Elke Theander; Arne Hansen; Manel Ramos-Casals; Thomas Dörner; Stefano Bombardieri; Eric Hachulla; Johan G Brun; Aike A Kruize; Sonja Praprotnik; Matija Tomsic; Jacques-Eric Gottenberg; Valerie Devauchelle; Salvatore Devita; Cristina Vollenweider; Thomas Mandl; Athanasios Tzioufas; Steven Carsons; Alain Saraux; Nurhan Sutcliffe; Claudio Vitali; Simon J Bowman
Journal:  Ann Rheum Dis       Date:  2011-02-22       Impact factor: 19.103

7.  Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects.

Authors:  Trond Ove R Hjelmervik; Kjell Petersen; Inge Jonassen; Roland Jonsson; Anne Isine Bolstad
Journal:  Arthritis Rheum       Date:  2005-05

8.  Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome.

Authors:  Jacques-Eric Gottenberg; Nicolas Cagnard; Carlo Lucchesi; Franck Letourneur; Sylvie Mistou; Thierry Lazure; Sebastien Jacques; Nathalie Ba; Marc Ittah; Christine Lepajolec; Marc Labetoulle; Marc Ardizzone; Jean Sibilia; Catherine Fournier; Gilles Chiocchia; Xavier Mariette
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

9.  The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients.

Authors:  Hennie G Raterman; Saskia Vosslamber; Sander de Ridder; Michael T Nurmohamed; Willem F Lems; Maarten Boers; Mark van de Wiel; Ben A C Dijkmans; Cornelis L Verweij; Alexandre E Voskuyl
Journal:  Arthritis Res Ther       Date:  2012-04-27       Impact factor: 5.156

10.  MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome.

Authors:  Naomi I Maria; Zana Brkic; Matti Waris; Cornelia G van Helden-Meeuwsen; Kim Heezen; Joop P van de Merwe; Paul L van Daele; Virgil A S H Dalm; Hemmo A Drexhage; Marjan A Versnel
Journal:  Ann Rheum Dis       Date:  2013-07-06       Impact factor: 19.103
  10 in total
  1 in total

1.  Tear cathepsin S as a candidate biomarker for Sjögren's syndrome.

Authors:  Sarah F Hamm-Alvarez; Srikanth R Janga; Maria C Edman; Sara Madrigal; Mihir Shah; Starleen E Frousiakis; Kavita Renduchintala; Jay Zhu; Seth Bricel; Kimberly Silka; Dianne Bach; Martin Heur; Stratos Christianakis; Daniel G Arkfeld; John Irvine; Wendy J Mack; William Stohl
Journal:  Arthritis Rheumatol       Date:  2014-07       Impact factor: 10.995
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.